Home World News FDA Approves Sacituzumab Govitecan-hziy as Monotherapy and in Combination with Pembrolizumab for...

FDA Approves Sacituzumab Govitecan-hziy as Monotherapy and in Combination with Pembrolizumab for First-Line Treatment of TNBC

August 5, 2026

151

Evidence for efficacy is based on the results from the ASCENT-03 and ASCENT-04/KEYNOTE D-19 studies